estrone has been researched along with Premenstrual Dysphoric Disorder in 1 studies
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.
Premenstrual Dysphoric Disorder: A condition in which a woman suffers from severe depression, irritability, and tension before MENSTRUATION. Premenstrual dysphoric disorder (PMDD) may involve a wide range of physical or emotional symptoms, which are more severe and debilitating than those seen with premenstrual syndrome (PMS), and which include at least one mood-related symptom. Symptoms usually stop when, or shortly after, menstruation begins.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Nguyen, TV | 1 |
Reuter, JM | 1 |
Gaikwad, NW | 1 |
Rotroff, DM | 1 |
Kucera, HR | 1 |
Motsinger-Reif, A | 1 |
Smith, CP | 1 |
Nieman, LK | 1 |
Rubinow, DR | 1 |
Kaddurah-Daouk, R | 1 |
Schmidt, PJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Central Nervous System Effects of Pharmacologically Induced Hypogonadotropic Hypogonadism With and Without Estrogen and Progesterone Replacement[NCT00001322] | Phase 1/Phase 2 | 100 participants (Actual) | Interventional | 1994-06-09 | Completed | ||
The Treatment of Menstrually-Related Mood Disorders With the Gonadotropin Releasing Hormone (GnRH) Agonist, Depot Leuprolide Acetate (Lupron)[NCT00001259] | Phase 1 | 60 participants (Actual) | Interventional | 1992-08-11 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures the severity of symptoms accompanying depression. Each item has a minimum score of 0 and a maximum score of 3, with higher numbers consistent with more severe symptoms. The score of each item is summed to amount the overall BDI score, with a minimum score of 0 and a maximum score of 63. Higher BDI scores are consistent with more severe depression. Score of 16 or greater is consistent with clinical depression.~Each participant completed the BDI every 2 weeks during each of the study phases (i.e., GnRH agonist alone, estradiol and progesterone) throughout the 6-month study. Outcome measures reported consist of the average of two BDI scores from each phase of the study: the last 4 weeks of the GnRH agonist alone (phase 1), during the 4-week long estradiol phase (phase 2: weeks 2 and 4 of estradiol) and the 4-week long progesterone phase (phase 2: weeks 2 and 4 of progesterone)." (NCT00001322)
Timeframe: Phase 1: Weeks 6 and 8 or 10 and 12; Phase 2: Weeks 2 and 4 of estradiol or progesterone
Intervention | Units on a scale (Mean) |
---|---|
Phase 1 - Lupron | 1.4 |
Phase 2 - Estradiol | 1 |
Phase 2 - Progesterone | 1.1 |
"The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures the severity of symptoms accompanying depression. Each item has a minimum score of 0 and a maximum score of 3, with higher numbers consistent with more severe symptoms. The score of each item is summed to amount the overall BDI score, with a minimum score of 0 and a maximum score of 63. Higher BDI scores are consistent with more severe depression. Score of 16 or greater is consistent with clinical depression.~Each participant completed the BDI every 2 weeks during each of the study phases throughout the 6-month study. Outcome measures reported consist of the average of two BDI scores from each phase of the study: the last 4 weeks of the GnRH agonist alone; weeks 6 and 8 of placebo alone; during the 4-week long estradiol phase (weeks 2 and 4 of estradiol) and the 4-week long progesterone phase (weeks 2 and 4 of progesterone)." (NCT00001259)
Timeframe: Placebo: Weeks 6 and 8 of Placebo; Lupron only: Weeks 6 and 8 or 10 and 12; Estradiol or progesterone: Weeks 2 and 4
Intervention | score on a scale (Mean) |
---|---|
Placebo | 2.6 |
GnRH Agonist Injections (Lupron-L Only) | 3.0 |
Estradiol | 5.3 |
Progesterone | 3.6 |
1 trial available for estrone and Premenstrual Dysphoric Disorder
Article | Year |
---|---|
The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback.
Topics: Adult; Cross-Over Studies; Desoxycorticosterone; Estradiol; Estrone; Female; Humans; Leuprolide; Met | 2017 |
The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback.
Topics: Adult; Cross-Over Studies; Desoxycorticosterone; Estradiol; Estrone; Female; Humans; Leuprolide; Met | 2017 |
The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback.
Topics: Adult; Cross-Over Studies; Desoxycorticosterone; Estradiol; Estrone; Female; Humans; Leuprolide; Met | 2017 |
The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback.
Topics: Adult; Cross-Over Studies; Desoxycorticosterone; Estradiol; Estrone; Female; Humans; Leuprolide; Met | 2017 |